The treatment of type 2 diabetes mellitus (T2DM) has undergone a fundamental change since the introduction of new-age antidiabetic drugs; such as dipeptidyl peptidase-4 (DPP-4) inhibitors. DPP-4 inhibitors elevate endogenous glucagon-like peptide 1 (GLP-1) concentrations, which stimulates insulin secretion and inhibits glucagon secretion. DPP-4 inhibitors are bodyweight neutral, poses a favorable safety profile, do not elevate intrinsic hypoglycemia risk, and have demonstrated cardioprotective and nephroprotective benefits.
1 DPP-4 inhibitors have been incorporated into many national and international guidelines available for the management of patients with T2DM. DPP-4 inhibitors are positioned as second-line therapy by The American Diabetes Association and European Association for the Study of Diabetes alongside with sulfonylureas, thiazolidinediones, GLP-1 agonists, and insulin.…
